Boniva

Osteoporosis, Malignant Neoplasms, Bone Metastases + 1 more

Treatment

2 FDA approvals

20 Active Studies for Boniva

Treatment for

Osteoporosis

What is Boniva

IbandronateThe Generic name of this drug

Treatment SummaryIbandronate, also known as BM 21.0955, is a type of medication used to prevent and treat bone loss in postmenopausal women. It is a third-generation drug that is similar to zoledronic acid, minodronic acid and risedronic acid. Ibandronate has been used to treat bone loss in dogs since 1993, and it was approved by the FDA in 2003.

Bonivais the brand name

image of different drug pills on a surface

Boniva Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Boniva

Ibandronate

2005

Approved as Treatment by the FDA

Ibandronate, otherwise known as Boniva, is approved by the FDA for 2 uses which include Osteoporosis and Osteoporosis .

Osteoporosis

Helps manage Osteoporosis

Osteoporosis

Helps manage Osteoporosis

Effectiveness

How Boniva Affects PatientsIbandronate is a medicine used to help prevent and treat osteoporosis in postmenopausal women. It is a relatively safe drug, and its effects can last a long time. Patients should be aware of the potential side effects such as stomach issues, low calcium, muscle pain, jaw damage, and kidney problems.

How Boniva works in the bodyBisphosphonates are taken into the body, where they bind to bone. This triggers the osteoclasts (cells that break down bone) to become acidic. This causes the bisphosphonates to be released from the bone and taken up by the osteoclasts. The bisphosphonates stop the osteoclasts from doing their job, which stops the bone from being broken down. Nitrogen containing bisphosphonates such as ibandronate also inhibit proteins that are important for cell survival. Without these proteins, cells die, causing tumor cells to die as well.

When to interrupt dosage

The advocated dosage of Boniva is contingent upon the diagnosed condition, including Bone Metastases, Malignant Neoplasms and Osteoporosis. The dose also fluctuates as per the method of delivery outlined in the table below.

Condition

Dosage

Administration

Malignant Neoplasms

, 3.0 mg/mL, 150.0 mg, 1.0 mg, 3.0 mg, 50.0 mg, 2.0 mg, 6.0 mg, 2.5 mg, 1.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous

Breast Cancer

, 3.0 mg/mL, 150.0 mg, 1.0 mg, 3.0 mg, 50.0 mg, 2.0 mg, 6.0 mg, 2.5 mg, 1.0 mg/mL

Bone Metastases

, 3.0 mg/mL, 150.0 mg, 1.0 mg, 3.0 mg, 50.0 mg, 2.0 mg, 6.0 mg, 2.5 mg, 1.0 mg/mL

Osteoporosis

, 3.0 mg/mL, 150.0 mg, 1.0 mg, 3.0 mg, 50.0 mg, 2.0 mg, 6.0 mg, 2.5 mg, 1.0 mg/mL

Warnings

Boniva Contraindications

Condition

Risk Level

Notes

Esophageal Strictures

Do Not Combine

Hypocalcemia

Do Not Combine

Esophagus

Do Not Combine

Esophageal Achalasia

Do Not Combine

Orthostatic Intolerance

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Ibandronate may interact with Pulse Frequency

There are 20 known major drug interactions with Boniva.

Common Boniva Drug Interactions

Drug Name

Risk Level

Description

Hydroxyzine

Major

The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Hydroxyzine.

Mobocertinib

Major

The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mobocertinib.

Ziprasidone

Major

The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ziprasidone.

Abexinostat

Minor

The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Abexinostat.

Aceprometazine

Minor

The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aceprometazine.

Boniva Toxicity & Overdose RiskSigns of ibandronate overdose include low calcium and phosphorus levels, stomach pain, indigestion, esophagitis, and ulcers. To reduce the amount of unabsorbed drug, patients can drink milk or take antacids. Treatment for an ibandronate overdose includes providing intravenous electrolytes, and dialysis is not known to be effective in removing the drug from the bloodstream.

image of a doctor in a lab doing drug, clinical research

Boniva Novel Uses: Which Conditions Have a Clinical Trial Featuring Boniva?

At present, 729 active clinical trials are underway to ascertain the effectiveness of Boniva in ameliorating Bone Metastases, Malignant Neoplasms and Osteoporosis.

Condition

Clinical Trials

Trial Phases

Osteoporosis

34 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3

Breast Cancer

26 Actively Recruiting

Phase 2, Phase 1, Not Applicable

Bone Metastases

7 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 3

Malignant Neoplasms

0 Actively Recruiting